Deep Track Capital LP acquired a new position in shares of Galapagos NV (NASDAQ:GLPG - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 780,778 shares of the biotechnology company's stock, valued at approximately $21,471,000. Deep Track Capital LP owned about 1.18% of Galapagos as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. R Squared Ltd acquired a new stake in shares of Galapagos during the fourth quarter worth about $26,000. GAMMA Investing LLC lifted its position in Galapagos by 77.4% during the 4th quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company's stock worth $61,000 after acquiring an additional 974 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Galapagos by 45.9% in the 4th quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company's stock valued at $247,000 after purchasing an additional 2,824 shares during the last quarter. QRG Capital Management Inc. grew its stake in shares of Galapagos by 21.7% in the 4th quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company's stock valued at $288,000 after purchasing an additional 1,866 shares during the last quarter. Finally, XTX Topco Ltd increased its holdings in shares of Galapagos by 137.8% in the fourth quarter. XTX Topco Ltd now owns 19,833 shares of the biotechnology company's stock valued at $545,000 after purchasing an additional 11,492 shares during the period. 32.46% of the stock is owned by hedge funds and other institutional investors.
Galapagos Trading Down 3.2 %
GLPG stock opened at $26.27 on Wednesday. The firm has a 50 day moving average of $25.43 and a 200-day moving average of $26.05. Galapagos NV has a 12-month low of $22.36 and a 12-month high of $31.23.
Galapagos (NASDAQ:GLPG - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The biotechnology company reported ($2.47) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($2.24). The business had revenue of $97.33 million during the quarter, compared to the consensus estimate of $72.22 million. Sell-side analysts forecast that Galapagos NV will post -1.6 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of research firms recently weighed in on GLPG. StockNews.com lowered shares of Galapagos from a "hold" rating to a "sell" rating in a research report on Friday, April 25th. Morgan Stanley lowered shares of Galapagos from an "equal weight" rating to an "underweight" rating and dropped their price target for the stock from $31.00 to $22.00 in a research note on Friday, February 14th. TD Cowen downgraded shares of Galapagos from a "strong-buy" rating to a "strong sell" rating in a research report on Thursday, January 9th. Finally, Barclays reissued an "underweight" rating on shares of Galapagos in a research note on Thursday, January 23rd. Five analysts have rated the stock with a sell rating and four have issued a hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Reduce" and an average price target of $25.33.
View Our Latest Research Report on GLPG
About Galapagos
(
Free Report)
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Galapagos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galapagos wasn't on the list.
While Galapagos currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
